KHK7791

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia

Trial Timeline

Dec 27, 2018 → Nov 26, 2019

About KHK7791

KHK7791 is a phase 2 stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03831607. Target conditions include Hyperphosphatemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT04771780Phase 3Completed
NCT04766385Phase 3Completed
NCT03831607Phase 2Completed

Competing Products

20 competing products in Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
EOS789 + Placebo + RenvelaChugai PharmaceuticalPhase 1
33
DS-2330b PIB + Placebo + Sevelamer + DS-2330b TabletDaiichi SankyoPhase 1
33
ASP1585 + Placebo + Sevelamer hydrochlorideAstellas PharmaPhase 2
52
ASP1585Astellas PharmaPhase 2
52
the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlacebpKyowa KirinPhase 2
52
KHK7791 + PlaceboKyowa KirinPhase 3
77
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlaceboKyowa KirinPhase 3
77
KHK7791Kyowa KirinPhase 3
77
KHK7791 + PlaceboKyowa KirinPhase 2
52
KHK7791Kyowa KirinPhase 3
77
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HClNovartisPhase 2
52
SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3
77
PA21Kissei PharmaceuticalPhase 3
76
Placebo + Sevelamer Carbonate (GZ419831)SanofiPhase 3
76
Placebo + Sevelamer carbonateSanofiPhase 2
51
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tabletBayerPre-clinical
20
Lanthanum Carbonate (Fosrenol, BAY77-1931)BayerPre-clinical
20
Lanthanum Carbonate (BAY77-1931)BayerPhase 2
49